Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Genetics and pathogenesis of methemoglobinemia

Josef T Prchal, MD
Section Editors
Stanley L Schrier, MD
Benjamin A Raby, MD, MPH
Deputy Editor
Jennifer S Tirnauer, MD


Methemoglobinemia occurs when an imbalance due to either increased methemoglobin production or decreased methemoglobin reduction is present. Inherited and acquired processes resulting in excess methemoglobin will be described here. The diagnosis and treatment of methemoglobinemia is described separately. (See "Clinical features, diagnosis, and treatment of methemoglobinemia".)


Methemoglobin is an altered state of hemoglobin in which the ferrous (Fe++) irons of heme are oxidized to the ferric (Fe+++) state. The ferric hemes of methemoglobin are unable to bind oxygen. In addition, the oxygen affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased [1]; as a result, the oxygen dissociation curve is "left-shifted" and oxygen delivery to the tissues is impaired (figure 1). (See "Genetic disorders of hemoglobin oxygen affinity".)

Thus, the patient with increased concentrations of methemoglobin has a functional anemia, to the extent that the circulating methemoglobin-containing molecules are unable to carry oxygen, and the remaining hemoglobin, because of its increased oxygen affinity, has a decreased ability to deliver oxygen to the tissues.

Formation — During the formation of oxyhemoglobin from deoxyhemoglobin and molecular oxygen, one electron is partially transferred from heme iron to the bound oxygen, forming a ferric-superoxide anion complex (Fe3+—O2-) [2]. During deoxygenation, most of the oxygen leaves the molecule as molecular oxygen, but a small amount leaves as a superoxide (O2-) radical. Under the latter circumstance, the partially transferred electron is not returned to the iron moiety, leaving the heme iron in the ferric state (ie, methemoglobin). This autooxidation of hemoglobin occurs spontaneously at a slow rate in normal individuals, converting 0.5 to 3 percent of the available hemoglobin to methemoglobin per day [3,4].

Methemoglobin is also formed from the oxidation of hemoglobin heme iron via reactions with free radicals and endogenous compounds, including hydrogen peroxide (H2O2), nitric oxide (NO), O2-, and hydroxyl radical (OH•) [5,6]. Exogenous compounds may oxidize hemoglobin to methemoglobin directly, by means of a metabolic derivative or by generating O2- and H2O2 during their metabolism.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jan 09, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Darling R, Roughton F. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. Am J Physiol 1942; 137:56.
  2. Misra HP, Fridovich I. The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem 1972; 247:6960.
  5. Jaffe E, Hultquist D. Cytochrome b5 reductase deficiency and enzymopenic hereditary methemoglobinemia. In: The Metabolic and Molecular Bases of Inherited Disease, 7th ed, Scriver C, Beaudet A, Sly W, Valle D (Eds), McGraw Hill, New York 1995. Vol 3, p.3399.
  6. Feelisch M, Kubitzek D, Werringloer J. The oxyhemoglobin assay. In: Methods in Nitric Oxide Research, Feelisch M, Stamler J (Eds), John Wiley and Sons, New York 1996. p.453.
  7. SCOTT EM, GRIFFITH IV. The enzymic defect of hereditary methemoglobinemia: diaphorase. Biochim Biophys Acta 1959; 34:584.
  8. Gibson QH. The reduction of methaemoglobin in red blood cells and studies on the cause of idiopathic methaemoglobinaemia. Biochem J 1948; 42:13.
  9. SCOTT EM, McGRAW JC. Purification and properties of diphosphopyridine nucleotide diaphorase of human erythrocytes. J Biol Chem 1962; 237:249.
  10. Passon PG, Hultquist DE. Soluble cytochrome b 5 reductase from human erythrocytes. Biochim Biophys Acta 1972; 275:62.
  11. Kuma F, Ishizawa S, Hirayama K, Nakajima H. Studies on methemoglobin reductase. I. Comparative studies of diaphorases from normal and methemoglobinemic erythrocytes. J Biol Chem 1972; 247:550.
  12. Kiese M. Die reduktion des hamiglobins. Biochem Z 1944; 316:264.
  13. Warburg O, Kubowitz F, Christian W. Uber die katalytische wirkung von methlenblau in lebenden zellen. Biochem Z 1930; 227:245.
  14. Yubisui T, Takeshita M, Yoneyama Y. Reduction of methemoglobin through flavin at the physiological concentration by NADPH-flavin reductase of human erythrocytes. J Biochem 1980; 87:1715.
  15. Sass MD, Caruso CJ, Farhangi M. TPNH-methemoglobin reductase deficiency: a new red-cell enzyme defect. J Lab Clin Med 1967; 70:760.
  16. Rosen PJ, Johnson C, McGehee WG, Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1971; 75:83.
  17. Stuhlmeier KM, Kao JJ, Wallbrandt P, et al. Antioxidant protein 2 prevents methemoglobin formation in erythrocyte hemolysates. Eur J Biochem 2003; 270:334.
  18. Maran J, Guan Y, Ou CN, Prchal JT. Heterogeneity of the molecular biology of methemoglobinemia: a study of eight consecutive patients. Haematologica 2005; 90:687.
  19. Iyanagi T, Watanabe S, Anan KF. One-electron oxidation-reduction properties of hepatic NADH-cytochrome b5 reductase. Biochemistry 1984; 23:1418.
  20. Strittmatter P. The reaction sequence in electron transfer in the reduced nicotinamide adenine dinucleotide-cytochrome b5 reductase system. J Biol Chem 1965; 240:4481.
  21. Tomatsu S, Kobayashi Y, Fukumaki Y, et al. The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. Gene 1989; 80:353.
  22. Pietrini G, Carrera P, Borgese N. Two transcripts encode rat cytochrome b5 reductase. Proc Natl Acad Sci U S A 1988; 85:7246.
  23. Pietrini G, Aggujaro D, Carrera P, et al. A single mRNA, transcribed from an alternative, erythroid-specific, promoter, codes for two non-myristylated forms of NADH-cytochrome b5 reductase. J Cell Biol 1992; 117:975.
  24. Mota Vieira L, Kaplan JC, Kahn A, Leroux A. Heterogeneity of the rat NADH-cytochrome-b5-reductase transcripts resulting from multiple alternative first exons. Eur J Biochem 1994; 220:729.
  25. Bulbarelli A, Valentini A, DeSilvestris M, et al. An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans. Blood 1998; 92:310.
  26. Tamura M, Yubisui T, Takeshita M, et al. Structural comparison of bovine erythrocyte, brain, and liver NADH-cytochrome b5 reductase by HPLC mapping. J Biochem 1987; 101:1147.
  27. Borgese N, Pietrini G. Distribution of the integral membrane protein NADH-cytochrome b5 reductase in rat liver cells, studied with a quantitative radioimmunoblotting assay. Biochem J 1986; 239:393.
  28. Zenno S, Hattori M, Misumi Y, et al. Molecular cloning of a cDNA encoding rat NADH-cytochrome b5 reductase and the corresponding gene. J Biochem 1990; 107:810.
  29. Yubisui T, Naitoh Y, Zenno S, et al. Molecular cloning of cDNAs of human liver and placenta NADH-cytochrome b5 reductase. Proc Natl Acad Sci U S A 1987; 84:3609.
  30. Ozols J, Korza G, Heinemann FS, et al. Complete amino acid sequence of steer liver microsomal NADH-cytochrome b5 reductase. J Biol Chem 1985; 260:11953.
  31. Yubisui T, Miyata T, Iwanaga S, et al. Complete amino acid sequence of NADH-cytochrome b5 reductase purified from human erythrocytes. J Biochem 1986; 99:407.
  32. Page DH, El-Hosseiny F, Winkler K. Behaviour of single wood fibres under axial tensile strain. Nature 1971; 229:252.
  33. Kitajima S, Yasukochi Y, Minakami S. Purification and properties of human erythrocyte membrane NADH-cytochrome b5 reductase. Arch Biochem Biophys 1981; 210:330.
  34. Francois. A case of congenital cyanosis without an apparent cause. Bull Acad Roy Med Belg 1845; 4:698.
  35. Hitzenberger K. Autotoxic cyanosis due to intraglobular methemoglobinemia. Wien Arch Med 1932; 23:85.
  36. Gibson QH. Historical note: methemoglobinemia--long ago and far away. Am J Hematol 1993; 42:3.
  37. Percy MJ, Gillespie MJ, Savage G, et al. Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. Blood 2002; 100:3447.
  38. Gibson Q. Introduction: congenital methemoglobinemia revisited. Blood 2002; 100:3445.
  39. Dekker J, Eppink MH, van Zwieten R, et al. Seven new mutations in the nicotinamide adenine dinucleotide reduced-cytochrome b(5) reductase gene leading to methemoglobinemia type I. Blood 2001; 97:1106.
  40. Board PG, Pidcock ME. Methaemoglobinaemia resulting from heterozygosity for two NADH-methaemoglobin reductase variants: characterization as NADH-ferricyanide reductase. Br J Haematol 1981; 47:361.
  41. González R, Estrada M, Wade M, et al. Heterogeneity of hereditary methaemoglobinaemia: a study of 4 Cuban families with NADH-Methaemoglobin reductase deficiency including a new variant (Santiago de Cuba variant). Scand J Haematol 1978; 20:385.
  42. Jaffe E. Hereditary methemoglobinemias associated with abnormalities in the metabolism of erythrocytes. Am J Med 1962; 32:512.
  43. Waller HD. Inherited methemoglobinemia (enzyme deficiencies). Humangenetik 1970; 9:217.
  44. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med 1968; 279:1127.
  45. SCOTT EM, HOSKINS DD. Hereditary methemoglobinemia in Alaskan Eskimos and Indians. Blood 1958; 13:795.
  46. SCOTT EM. The relation of diaphorase of human erythrocytes to inheritance of methemoglobinemia. J Clin Invest 1960; 39:1176.
  48. Andreeva A, Dmitrieva M, Levina A, et al. Molecular basis for disorders in the functional properties of hemoglobin in patients with enzymopenic methemoglobinemia. In: Papers of the 49th Scientific Session of the Central Scientific Research Institute of Hematology and Blood Tra, 1979. p.73.
  49. Ilinskaia, I, Derviz, et al. Enzymatic methemoglobinemia. In: Papers of the symposium: Biological problems of the north, State University, Yakutsk, 1974. p.226.
  50. Prchal JT, Borgese N, Moore MR, et al. Congenital methemoglobinemia due to methemoglobin reductase deficiency in two unrelated American black families. Am J Med 1990; 89:516.
  51. Shirabe K, Yubisui T, Borgese N, et al. Enzymatic instability of NADH-cytochrome b5 reductase as a cause of hereditary methemoglobinemia type I (red cell type). J Biol Chem 1992; 267:20416.
  52. Katsube T, Sakamoto N, Kobayashi Y, et al. Exonic point mutations in NADH-cytochrome B5 reductase genes of homozygotes for hereditary methemoglobinemia, types I and III: putative mechanisms of tissue-dependent enzyme deficiency. Am J Hum Genet 1991; 48:799.
  53. Jenkins MM, Prchal JT. A novel mutation found in the 3' domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. Blood 1996; 87:2993.
  54. Jenkins MM, Prchal JT. A high-frequency polymorphism of NADH-cytochrome b5 reductase in African-Americans. Hum Genet 1997; 99:248.
  55. Leroux A, Junien C, Kaplan J, Bamberger J. Generalised deficiency of cytochrome b5 reductase in congenital methaemoglobinaemia with mental retardation. Nature 1975; 258:619.
  56. Takeshita M, Tamura M, Kugi M, et al. Decrease of palmitoyl-CoA elongation in platelets and leukocytes in the patient of hereditary methemoglobinemia associated with mental retardation. Biochem Biophys Res Commun 1987; 148:384.
  57. Prchal J. Hemoglobins continue to fascinate and surprise. The Hematologist 2006; 3:1.
  58. Vieira LM, Kaplan JC, Kahn A, Leroux A. Four new mutations in the NADH-cytochrome b5 reductase gene from patients with recessive congenital methemoglobinemia type II. Blood 1995; 85:2254.
  59. Shirabe K, Landi MT, Takeshita M, et al. A novel point mutation in a 3' splice site of the NADH-cytochrome b5 reductase gene results in immunologically undetectable enzyme and impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with type II hereditary methemoglobinemia. Am J Hum Genet 1995; 57:302.
  60. Jenkins MM, Prchal JT. A novel mutation found in the 3' domain of NADH-cytochrome B5 reductase in an African-American family with type I congenital methemoglobinemia. Blood 1996; 87:2993.
  61. Kobayashi Y, Fukumaki Y, Yubisui T, et al. Serine-proline replacement at residue 127 of NADH-cytochrome b5 reductase causes hereditary methemoglobinemia, generalized type. Blood 1990; 75:1408.
  62. Manabe J, Arya R, Sumimoto H, et al. Two novel mutations in the reduced nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase gene of a patient with generalized type, hereditary methemoglobinemia. Blood 1996; 88:3208.
  63. Shirabe K, Fujimoto Y, Yubisui T, Takeshita M. An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. J Biol Chem 1994; 269:5952.
  64. Owen EP, Berens J, Marinaki AM, et al. Recessive congenital methaemoglobinaemia type II a new mutation which causes incorrect splicing in the NADH-cytochrome b5 reductase gene. J Inherit Metab Dis 1997; 20:610.
  65. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol 1993; 42:7.
  66. Beutler, E. Methemoglobinemia and other causes of cyanosis. In: Williams' Hematology, 5th ed, Beutler, E, Lichtman, MA, Coller, B, Kipps, TJ (Eds), McGraw-Hill, New York, 1995, p. 654.
  67. Crowley MA, Mollan TL, Abdulmalik OY, et al. A hemoglobin variant associated with neonatal cyanosis and anemia. N Engl J Med 2011; 364:1837.
  68. Hackett CS, Strittmatter P. Covalent cross-linking of the active sites of vesicle-bound cytochrome b5 and NADH-cytochrome b5 reductase. J Biol Chem 1984; 259:3275.
  69. Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med 1986; 314:757.
  70. Giordano SJ, Kaftory A, Steggles AW. A splicing mutation in the cytochrome b5 gene from a patient with congenital methemoglobinemia and pseudohermaphrodism. Hum Genet 1994; 93:568.
  71. TOWNES PL, MORRISON M. Investigation of the defect in a variant of hereditary methemoglobinemia. Blood 1962; 19:60.
  72. Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996; 14:394.
  73. Daly JS, Hultquist DE, Rucknagel DL. Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase. J Med Genet 1983; 20:307.
  74. Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore) 2004; 83:265.
  75. Falkenhahn M, Kannan S, O'Kane M. Unexplained acute severe methaemoglobinaemia in a young adult. Br J Anaesth 2001; 86:278.
  76. Faley B, Chase H. A Case of Severe Amyl Nitrate Induced Methemoglobinemia Managed with Methylene Blue. J Clinic Toxicol 2012; 2:127.
  77. Khan U, Hadid T. RUSH for G6PD! Blood 2016; 128:2742.
  78. Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med 2004; 164:1192.
  79. Kane GC, Hoehn SM, Behrenbeck TR, Mulvagh SL. Benzocaine-induced methemoglobinemia based on the Mayo Clinic experience from 28 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors. Arch Intern Med 2007; 167:1977.
  80. Chowdhary S, Bukoye B, Bhansali AM, et al. Risk of topical anesthetic-induced methemoglobinemia: a 10-year retrospective case-control study. JAMA Intern Med 2013; 173:771.
  81. Henry LR, Pizzini M, Delarso B, Ridge JA. Methemoglobinemia: early intraoperative detection by clinical observation. Laryngoscope 2004; 114:2025.
  82. Eng LI, Loo M, Fah FK. Diaphroase activity and variants in normal adults and newborns. Br J Haematol 1972; 23:419.
  83. Bartos HR, Desforges JF. Erythrocyte DPNH dependent diaphorase levels in infants. Pediatrics 1966; 37:991.
  84. ROSS JD. Deficient activity of DPNH-dependent methemoglobin diaphorase in cord blood erythrocytes. Blood 1963; 21:51.
  85. Yano SS, Danish EH, Hsia YE. Transient methemoglobinemia with acidosis in infants. J Pediatr 1982; 100:415.
  86. HEYMAN I. Methemoglobinemia in infants. Harefuah 1954; 46:144.
  87. Hegesh E, Shiloah J. Blood nitrates and infantile methemoglobinemia. Clin Chim Acta 1982; 125:107.
  88. Pollack ES, Pollack CV Jr. Incidence of subclinical methemoglobinemia in infants with diarrhea. Ann Emerg Med 1994; 24:652.
  89. Hanukoglu A, Danon PN. Endogenous methemoglobinemia associated with diarrheal disease in infancy. J Pediatr Gastroenterol Nutr 1996; 23:1.
  90. Comly H. Cyanosis in infants caused by nitrates in well water. JAMA 1945; 129:112.
  91. Kross BC, Ayebo AD, Fuortes LJ. Methemoglobinemia: nitrate toxicity in rural America. Am Fam Physician 1992; 46:183.
  92. Greer FR, Shannon M, American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Committee on Environmental Health. Infant methemoglobinemia: the role of dietary nitrate in food and water. Pediatrics 2005; 116:784.
  93. Knobeloch L, Saina B, Hogan A, et al. Blue babies and nitrate-contaminated well water. Environ Health Perspect 2011; 108:675.
  94. Fact sheet for nitrates and nitrites: http://www.atsdr.cdc.gov/toxfaqs/tf.asp?id=1186&tid=258 (Accessed on December 15, 2011).
  95. Chan TY. Vegetable-borne nitrate and nitrite and the risk of methaemoglobinaemia. Toxicol Lett 2011; 200:107.
  96. Katan MB. Nitrate in foods: harmful or healthy? Am J Clin Nutr 2009; 90:11.
  97. Thomson BM, Nokes CJ, Cressey PJ. Intake and risk assessment of nitrate and nitrite from New Zealand foods and drinking water. Food Addit Contam 2007; 24:113.
  98. Tamme T, Reinik M, Püssa T, et al. Dynamics of nitrate and nitrite content during storage of home-made and small-scale industrially produced raw vegetable juices and their dietary intake. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2010; 27:487.